Checkmate Pharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Checkmate Pharmaceuticals Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11018
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:23
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Checkmate Pharmaceuticals Inc (Checkmate Pharmaceuticals) is a clinical stage company that discovers and develops immunotherapies to provide new treatment options for patients and the healthcare providers. The company’s lead product candidate, CMP-001, is a CpG oligonucleotides (CpG-A ODN) that converts immunologically cold tumors to immunologically hot tumors. It also evaluates CMP-001-001, an open label study of intratumoral administration of CMP-001 in combination with pembrolizumab in patients with advanced cutaneous melanoma. Checkmate Pharmaceuticals is headquartered in Cambridge, Massachusetts, the US.

Checkmate Pharmaceuticals Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Checkmate Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Checkmate Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Checkmate Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Checkmate Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Checkmate Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Checkmate Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Checkmate Pharma Raises USD27 Million in Series B Preferred Financing 10
Checkmate Pharma Raises Additional USD5 Million in Venture Financing 11
Checkmate Pharmaceuticals Raises USD20 Million in Series A Round of Financing 12
Partnerships 13
Checkmate Pharma Enters into Partnership with Merck and Pfizer 13
Biodesix Enters into Research Agreement with Checkmate Pharma 14
Genocea Biosciences Enters into Research Agreement with Checkmate Pharma 15
Licensing Agreements 16
Checkmate Pharma Amends Licensing Agreement with Kuros Biosciences 16
Checkmate Pharmaceuticals Inc – Key Competitors 17
Checkmate Pharmaceuticals Inc – Key Employees 18
Checkmate Pharmaceuticals Inc – Locations And Subsidiaries 19
Head Office 19
Recent Developments 20
Clinical Trials 20
Apr 24, 2018: Checkmate Pharmaceuticals Announces Start of Phase 1b Trial of CMP-001 in Combination with Anti-PD-L1 Immunotherapy in Anti-PD-1/PD-L1 Resistant Advanced Non-Small Cell Lung Cancer 20
Apr 17, 2018: Checkmate Pharmaceuticals Presents Clinical Data at the 2018 American Association for Cancer Research (AACR) Annual Meeting 21
Appendix 23
Methodology 23
About GlobalData 23
Contact Us 23
Disclaimer 23

List of Tables
Checkmate Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts 2
Checkmate Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Checkmate Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Checkmate Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Checkmate Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Checkmate Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Checkmate Pharma Raises USD27 Million in Series B Preferred Financing 10
Checkmate Pharma Raises Additional USD5 Million in Venture Financing 11
Checkmate Pharmaceuticals Raises USD20 Million in Series A Round of Financing 12
Checkmate Pharma Enters into Partnership with Merck and Pfizer 13
Biodesix Enters into Research Agreement with Checkmate Pharma 14
Genocea Biosciences Enters into Research Agreement with Checkmate Pharma 15
Checkmate Pharma Amends Licensing Agreement with Kuros Biosciences 16
Checkmate Pharmaceuticals Inc, Key Competitors 17
Checkmate Pharmaceuticals Inc, Key Employees 18

List of Figures
Checkmate Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Checkmate Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Checkmate Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Checkmate Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Checkmate Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Checkmate Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Checkmate Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Checkmate Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Checkmate Pharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • C&S Wholesale Grocers, Inc.:企業の戦略・SWOT・財務情報
    C&S Wholesale Grocers, Inc. - Strategy, SWOT and Corporate Finance Report Summary C&S Wholesale Grocers, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Oragenics Inc (OGEN):製薬・医療:M&Aディール及び事業提携情報
    Summary Oragenics Inc (Oragenics) focuses on the development and commercialization of novel antibiotics against infectious disease that includes treatments for oral mucositis, healthcare associated infections, obesity and dental disorders. The company develops its product candidates based on various …
  • Stem Cell Theranostics Inc-製薬・医療分野:企業M&A・提携分析
    Summary Stem Cell Theranostics Inc (Stem Cell Theranostics) is a biotechnology company that develops genetically-targeted therapies for heart failure. The company discovers and develops novel medicines for heart diseases using stem cell-derived, patient-specific cardiac disease models. It also devel …
  • Rada Electronic Industries Ltd.
    Rada Electronic Industries Ltd. - Strategy, SWOT and Corporate Finance Report Summary Rada Electronic Industries Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • IBC Solar AG:企業の戦略的SWOT分析
    IBC Solar AG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • CECO Environmental Corp (CECE):企業の財務・戦略的SWOT分析
    CECO Environmental Corp (CECE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Ariste Medical LLC:医療機器:M&Aディール及び事業提携情報
    Summary Ariste Medical LLC (Ariste) is a medical device company that develops drug eluting surgical implants. The company develops drug eluting tunneled dialysis catheter for hemodialysis, drug eluting mesh for hernia repair, and drug eluting vascular graft for peripheral bypass. It also develops dr …
  • UCB SA (UCB)-製薬・医療分野:企業M&A・提携分析
    Summary UCB SA (UCB) is a biopharmaceutical company that discovers and develops novel medicines and solutions to help treat various diseases. It principally focuses on developing products for the treatment of central nervous system (CNS) and immunology related conditions. The company's key medicines …
  • Cree, Inc.:戦略・SWOT・企業財務分析
    Cree, Inc. - Strategy, SWOT and Corporate Finance Report Summary Cree, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Shv Holdings N.V.:企業の戦略・SWOT・財務分析
    Shv Holdings N.V. - Strategy, SWOT and Corporate Finance Report Summary Shv Holdings N.V. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Checkmate Pharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Checkmate Pharmaceuticals Inc (Checkmate Pharmaceuticals) is a clinical stage company that discovers and develops immunotherapies to provide new treatment options for patients and the healthcare providers. The company’s lead product candidate, CMP-001, is a CpG oligonucleotides (CpG-A ODN) t …
  • Robert Bosch GmbH:企業の戦略的SWOT分析
    Robert Bosch GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • CohBar Inc (COB.U):企業の財務・戦略的SWOT分析
    Summary CohBar Inc (CohBar) is a developer of mitochondria based therapeutics. The company develops a class of drugs to treat a wide range of diseases associated with aging and metabolic dysfunction such as non-alcoholic steatohepatitis, obesity, type 2 diabetes, cancer, cardiovascular disease and C …
  • Emerson Electric Co (EMR)-エネルギー分野:企業M&A・提携分析
    Summary Emerson Electric Co. (Emerson) is a provider of infrastructure technologies and life cycle services for information and communication technology systems. The company offers hardware and software solutions for power, thermal and infrastructure management under the brands of Kop-Flex, jaure, a …
  • Petronas Dagangan Berhad (PETDAG):企業の財務・戦略的SWOT分析
    Petronas Dagangan Berhad (PETDAG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • University of Copenhagen:製薬・医療:M&Aディール及び事業提携情報
    Summary University of Copenhagen (UCPH) is a university and research institution that offers educational and research programs and services. The university’ services include graduate and undergraduate courses, research programs, master's programs, continuing education services, online courses, inter …
  • Crossject SA (ALCJ)-医療機器分野:企業M&A・提携分析
    Summary Crossject SA (Crossject) is a medical device company that develops injection systems. The company offers products which include methotrexate, epinephrin, sumatriptan, L15, naloxone, apomorphine, and midazolam. It uses its needle-free injection system to develop a pipeline of supergenerics by …
  • The Hackett Group, Inc. (HCKT):企業の財務・戦略的SWOT分析
    The Hackett Group, Inc. (HCKT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • hVIVO Plc (HVO):企業の財務・戦略的SWOT分析
    Summary hVIVO Plc (hVIVO), formerly Retroscreen Virology Ltd is a biopharma company that develops human-based analytical platform to accelerate drug discovery and development. The company enables organisations to discover drugs and diagnostics and accelerate new product development. It uses human di …
  • Bill & Melinda Gates Foundation-製薬・医療分野:企業M&A・提携分析
    Summary Bill & Melinda Gates Foundation (BMGF), formerly William H. Gates Foundation is a provider of health development programs. The foundation concentrates on improving healthcare, decrease poverty in America and provides access to information equipment. It offers global health services in the fi …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆